Study Suggests Bempedoic Acid Could Find Role in Primary Prevention

An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.

Related Keywords

United States ,American ,Campbellp Bempedoic ,Stevene Nissen ,Dhruv Kazi ,Scientific Sessions Of The American Diabetes Association ,Beth Israel Deaconess Medical Center ,American College Of Cardiology ,Outcomes Research ,Thoracic Institute At Cleveland Clinic ,Smith Center ,Scientific Sessions ,American Diabetes Association ,American College ,Thoracic Institute ,New England Journal ,Cardiac Critical Care Unit ,Primary Prevention ,Cardiovascular Events ,Lowering Drug Shown ,Cut Major Heart Related Events ,Heart Disease ,Statin Intolerant Patients ,High Risk Primary Prevention ,Cardiovascular Disease ,Statin Substitute ,Good Plan ,